Pelvipharm
Preclinical contract research organization focused on urogenital, sexual medicine, women’s health and related cardiometabolic disorders. Offers in vivo rodent disease models, ex vivo tissue pharmacology, neurophysiology and behavioral assays to evaluate pharmacological candidates and therapeutic approaches. Publishes and presents preclinical findings in scientific journals and meetings.
Industries
Nr. of Employees
small (1-50)
Pelvipharm
Montigny-le-bretonneux, Ile-de-France, France, Europe
Services
End-to-end design and conduct of rodent studies for urogenital, sexual dysfunction, women's health and cardiometabolic indications, including surgical, chemical and genetic models.
Functional assays on isolated tissues (corpus cavernosum, prostate, bladder, vagina, myometrium) to measure pharmacodynamic responses.
Electrophysiological recordings, reflex testing and behavioral protocols to assess neural control of sexual and urogenital functions.
End-to-end design and conduct of rodent studies for urogenital, sexual dysfunction, women's health and cardiometabolic indications, including surgical, chemical and genetic models.
Functional assays on isolated tissues (corpus cavernosum, prostate, bladder, vagina, myometrium) to measure pharmacodynamic responses.
Electrophysiological recordings, reflex testing and behavioral protocols to assess neural control of sexual and urogenital functions.
Expertise Areas
- Preclinical CRO for urogenital and gynecological research
- Animal model development and validation
- Ex vivo tissue pharmacology
- Neuropharmacology and behavioral assays
Key Technologies
- Rodent in vivo disease models
- Ex vivo tissue bath pharmacology
- Behavioral assays for sexual and ejaculatory function
- Electrophysiology and neural reflex recording
News & Updates
Preclinical pharmacology study reporting a β3-adrenoceptor agonist effect on bladder smooth muscle.
Review on serotonergic mechanisms relevant to premature ejaculation and therapeutic opportunities.
Description and validation of a testosterone-supplemented spontaneously hypertensive rat model combining ED and BPH features.
Study reporting c-fos activation following acute and repeated drug treatment in a preclinical model.
Preclinical pharmacology study reporting a β3-adrenoceptor agonist effect on bladder smooth muscle.
Review on serotonergic mechanisms relevant to premature ejaculation and therapeutic opportunities.
Description and validation of a testosterone-supplemented spontaneously hypertensive rat model combining ED and BPH features.
Study reporting c-fos activation following acute and repeated drug treatment in a preclinical model.